A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis

International Journal of Rheumatology

Volumn 2012, Issue , 2012, Pages

  Missala, I ^a   Kassner, U ^a   Steinhagen Thiessen, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; IMMUNE SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS;

EID: 84871847360     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2012/480784     Document Type: Review

References (68)

1. Jonasson L., Eriksson T., Dahle'n G. H., Lindblom B., Lipoprotein(a) and HLA-DRB1 and -DQB1 genes in coronary artery disease. Atherosclerosis 1997 133 1 111 114 2-s2.0-0030814416
2. Frostegård J., Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmunity Reviews 2002 1 4 233 237 2-s2.0-0042970311 10.1016/S1568-9972(02)00059-9 (Pubitemid 38340258)
3. Sari R. A., Polat M. F., Taysi S., Bakan E., Çapolu I., Serum Lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clinical Rheumatology 2002 21 6 520 524 2-s2.0-0036871122 10.1007/s100670200127 (Pubitemid 36054453)
4. Milioti N., Bermudez-Fajardo A., Penichet M. L., Oviedo-Orta E., Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clinical and Developmental Immunology 2008 2008 15 2-s2.0-45349090687 10.1155/2008/723539 723539 (Pubitemid 351845461)
5. Berg K., A new serum type system in man-the lp system. Acta pathologica et microbiologica Scandinavica 1963 59 369 382 2-s2.0-47649091099
6. Matthews K. A., Sowers M. F., Derby C. A., Stein E., Miracle-McMahill H., Crawford S. L., Pasternak R. C., Ethnic differences in cardiovascular risk factor burden among middle-aged women: study of women's health across the nation (SWAN). American Heart Journal 2005 149 6 1066 1073 2-s2.0-20544463468 10.1016/j.ahj.2004.08.027 (Pubitemid 40848152)
7. Kiechl S., Willeit J., Mayr M., Viehweider B., Oberhollenzer M., Kronenberg F., Wiedermann C. J., Oberthaler S., Xu Q., Witztum J. L., Tsimikas S., Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 Activity, and 10-year cardiovascular outcomes: prospective results from the bruneck study. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 8 1788 1795 2-s2.0-34547627109 10.1161/ATVBAHA.107.145805 (Pubitemid 47207175)
8. Nordestgaard B. G., Chapman M. J., Ray K., Borén J., Andreotti F., Watts G. F., Ginsberg H., Amarenco P., Catapano A., Descamps O. S., Fisher E., Kovanen P. T., Kuivenhoven J. A., Lesnik P., Masana L., Reiner Z., Taskinen M. R., Tokgözoglu L., Tybjærg-Hansen A., Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 2010 31 23 2844 2853 2-s2.0-78649888517 10.1093/eurheartj/ehq386
9. Lippi G., Franchini M., Targher G., Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. Clinica Chimica Acta 2011 412 11-12 797 801 2-s2.0-79954991685 10.1016/j.cca.2011.01.018
10. Howard G. C., Pizzo S. V., Lipoprotein(a) and its role in atherothrombotic disease. Laboratory Investigation 1993 69 4 373 386 2-s2.0-0027362951 (Pubitemid 23335837)
11. Romero F. I., Khamashta M. A., Hughes G. R. V., Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus 2000 9 3 206 209 2-s2.0-0034032719 (Pubitemid 30199264)
12. Haberland M. E., Fless G. M., Scanu A. M., Fogelman A. M., Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. The Journal of Biological Chemistry 1992 267 6 4143 4151 2-s2.0-0026768695
13. Romero F. I., Atsumi T., Tinahones F.J., Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. Arthritis and Rheumatism 1999 42 12 2606 2611 (Pubitemid 30327178)
14. Ylä-Herttuala S., Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Annals of Medicine 1991 23 5 561 567 2-s2.0-0026323623
15. Salonen J. T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J. L., Autoantibody against oxidised LDL and progression of carotid atherosclerosis. The Lancet 1992 339 8798 883 887 2-s2.0-0026586813
16. Maggi E., Bellazzi R., Gazo A., Seccia M., Bellomo G., Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney International 1994 46 3 869 876 2-s2.0-0028108018 (Pubitemid 24272047)
17. Ames P. R. J., Lupoli S., Alves J., Atsumi T., Edwards C., Iannaccone L., Khamashta M. A., Hughes G. R. V., Brancaccio V., The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. British Journal of Rheumatology 1997 36 10 1045 1050 2-s2.0-0030725625
18. Cerinic M. M., Valentini G., Sorano G. G., D'Angelo S., Cuomo G., Fenu L., Generini S., Cinotti S., Morfini M., Pignone A., Guiducci S., del Rosso A., Kalfin R., Das D., Marongiu F., Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Seminars in Arthritis and Rheumatism 2003 32 5 285 295 2-s2.0-0344511824 10.1053/sarh.2002.50011 (Pubitemid 36459278)
19. Scanu A. M., Fless G. M., Lipoprotein (a). Heterogeneity and biological relevance. Journal of Clinical Investigation 1990 85 6 1709 1715 2-s2.0-0025311925 (Pubitemid 20192939)
20. Lippi G., Caramaschi P., Montagnana M., Salvagno G. L., Volpe A., Guidi G., Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. Clinica Chimica Acta 2006 364 1-2 345 348 2-s2.0-31044448693 10.1016/j.cca.2005.07.015 (Pubitemid 43120666)
21. Asanuma Y., Kawai S., Aoshima H., Kaburaki J., Mizushima Y., Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis and Rheumatism 1999 42 3 443 447 10.1002/1529-0131(199904) 42:3<443::AID-ANR8>3.0.CO;2-Q (Pubitemid 29136091)
22. Lee Y. H., Choi S. J., Ji J. D., Seo H. S., Song G. G., Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clinical Rheumatology 2000 19 4 324 325 2-s2.0-0033859202 (Pubitemid 30612569)
23. Dursunolu D., Evrengül H., Polat B., Tanriverdi H., Çobankara V., Kaftan A., Kiliç M., Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatology International 2005 25 4 241 245 2-s2.0-20044362604 10.1007/s00296-004-0438-0 (Pubitemid 40767825)
24. Wang J., Hu B., Kong L., Cai H., Zhang C., Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clinica Chimica Acta 2008 390 1-2 67 71 2-s2.0-39749120397 10.1016/j.cca.2007.12.015
25. Kerekes G., Szekanecz Z., Dér H., Sándor Z., Lakos G., Muszbek L., Csipö I., Sipka S., Seres I., Paragh G., Kappelmayer J., Szomják E., Veres K., Szegedi G., Shoenfeld Y., Soltész P., Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. Journal of Rheumatology 2008 35 3 398 406 2-s2.0-40649091425 (Pubitemid 351374411)
26. 2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clinica Chimica Acta 2011 412 15-16 1332 1336 2-s2.0-79956325366 10.1016/j.cca.2011.03.029
27. McMahon M., Skaggs B. J., Sahakian L., Grossman J., FitzGerald J., Ragavendra N., Charles-Schoeman C., Chernishof M., Gorn A., Witztum J. L., Wong W. K., Weisman M., Wallace D. J., La Cava A., Hahn B. H., High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Annals of the Rheumatic Diseases 2011 70 9 1619 1624 2-s2.0-80051471532 10.1136/ard.2010.142737
28. 2-GPI-Lp(a) complexes in patients with systemic lupus erythematosus. Clinica Chimica Acta 2010 411 5-6 395 399 2-s2.0-75049086109 10.1016/j.cca.2009.12.008
29. Okawa-Takatsuji M., Aotsuka S., Sumiya M., Ohta H., Kawakami M., Sakurabayashi I., Clinical significance of the serum lipoprotein(a) level in patients with systemic lupus erythematosus: its elevation during disease flare. Clinical and Experimental Rheumatology 1996 14 5 531 536 2-s2.0-0029836174 (Pubitemid 26335476)
30. Kiss E., Fazekas B., Tarr T., Muszbek L., Zeher M., Szegedi G., Examination of lipid profile in patients with systemic lupus erythematosus: With a special focus on lipoprotein (a) in lupus nephritis. Orvosi Hetilap 2004 145 5 217 222 2-s2.0-1642617660 (Pubitemid 41258009)
31. Rantapää-Dahlqvist S., Neumann-Andersen G., Backman C., Dahlén G., Stegmayr B., Echocardiographic findings, lipids and lipoprotein(a) in patients with systemic lupus erythematosus. Clinical Rheumatology 1997 16 2 140 148 2-s2.0-1842290372 (Pubitemid 27119785)
32. Wanner C., Rader D., Bartens W., Kramer J., Brewer H. B., Schollmeyer P., Wieland H., Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Annals of Internal Medicine 1993 119 4 263 269 2-s2.0-0027492029 (Pubitemid 23319881)
33. Fujita T., Saito E., Ohi H., Yasugi T., Hatano M., Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome. Nephron 1992 61 1, article 122 2-s2.0-0026582227
34. Matsuda J., Gohchi K., Kawasugi K., Increased factor VIIa levels in systemic lupus erythematosus patients with lupus anticoagulant. International Journal of Hematology 1997 65 2 143 149 2-s2.0-0031081668 (Pubitemid 27102074)
35. Hughes G. R. V., The antiphospholipid syndrome: ten years on. The Lancet 1993 342 8867 341 344 2-s2.0-0027292423 10.1016/0140-6736(93)91477-4 (Pubitemid 23227565)
36. Atsumi T., Khamashta M. A., Andujar C., Leandro M. J., Amengual O., Ames P. R. J., Hughes G. R. V., Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. Journal of Rheumatology 1998 25 1 69 73 2-s2.0-0031985183 (Pubitemid 28060120)
37. Yamazaki M., Asakura H., Jokaji H., Saito M., Uotani C., Kumabashiri I., Morishita E., Aoshima K., Ikeda T., Matsuda T., Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thrombosis and Haemostasis 1994 71 4 424 427 2-s2.0-0028324892 (Pubitemid 24100665)
38. Bećarević M., Singh S., Majkić-Singh N., Lipoprotein (a) and apolipoprotein (a) in primary antiphospholipid syndrome. Clinical Biochemistry 2007 40 5-6 317 320 2-s2.0-33847316646 10.1016/j.clinbiochem.2006. 11.018 (Pubitemid 46321489)
39. Kritz H., Pidlich J., O'Grady J., Sinzinger H., Is a(n inborn) deficiency of prostacyclin synthesis stimulating plasma factor associated with increased lipoprotein(a)? Prostaglandins Leukotrienes and Essential Fatty Acids 1996 55 5 363 372 2-s2.0-0029987349 10.1016/S0952-3278(96)90043-5 (Pubitemid 26418521)
40. Yasuda S., Tsutsumi A., Chiba H., Yanai H., Miyoshi Y., Takeuchi R., Horita T., Atsumi T., Ichikawa K., Matsuura E., Koike T., β 2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000 152 2 337 346 2-s2.0-0033812286 10.1016/S0021-9150(99)00496-7
41. 2GPI) in the activation of plasminogen. Biochimica et Biophysica Acta 2006 1764 4 815 823 2-s2.0-33745157186 10.1016/j.bbapap.2005.12.020 (Pubitemid 44389496)
42. Wang J. J., Gong J.-B., Li H., Niu D. G., Han A.-Z., Wu J., Zhang C. N., Lipoprotein(a) complexes with Beta2-Glycoprotein I in patients with coronary artery disease. Journal of Atherosclerosis and Thrombosis 2012 19 1 81 89 2-s2.0-84863078747 10.5551/jat.9340
43. Wehr H., Rado M., Mendel T., Swiderska M., Bednarska-Makaruk M., Szirkowiec W., Changes in lipoprotein (a) [Lp(a)] level after an ischemic stroke. Neurologia i Neurochirurgia Polska 2004 38 3 197 200 2-s2.0-7044286193
44. Milionis H. J., Mittari V., Exarchakos G., Kalaitzidis R., Skevas A. T., Elisaf M. S., Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. European Journal of Clinical Investigation 2003 33 12 1045 1050 2-s2.0-0346250183 10.1111/j.1365-2362.2003.01275.x (Pubitemid 38019138)
45. Topçu-Shufta V., Begolli L., Kryeziu E., Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. Bosnian Journal of Basic Medical Sciences 2010 10 1 19 25 2-s2.0-77949414010
46. Kario K., Matsuo T., Kobayashi H., Matsuo M., Asada R., Koide M., High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thrombosis and Haemostasis 1995 74 4 1020 1024 2-s2.0-0028845960
47. Wållberg-Jonsson S., Uddhammar A., Dahlén G., Rantapää-Dahlqvist S., Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scandinavian Journal of Clinical and Laboratory Investigation 1995 55 4 309 315 2-s2.0-0029021025
48. Dahlén G. H., Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994 108 2 111 126 2-s2.0-0028129403 10.1016/0021-9150(94)90106- 6 (Pubitemid 24265884)
49. Carlson L. A., Hamsten A., Asplund A., Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. Journal of Internal Medicine 1989 226 4 271 276 2-s2.0-0024466520 (Pubitemid 19230908)
50. Safarova M. S., Trukhacheva E. P., Ezhov M. V., Afanas'eva O. I., Afanas'eva M. I., Tripoten' M. I., Liakishev A. A., Pokrovski S. N., Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels. Kardiologiia 2011 51 5 9 16 2-s2.0-80052384849
51. Cashin-Hemphill L., Mack W. J., Pogoda J. M., Sanmarco M. E., Azen S. P., Blankenhorn D. H., Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. The Journal of the American Medical Association 1990 264 23 3013 3017 2-s2.0-0025678697 10.1001/jama.264.23.3013
52. Goldberg A., Alagona P., Capuzzi D. M., Guyton J., Morgan J. M., Rodgers J., Sachson R., Samuel P., Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. American Journal of Cardiology 2000 85 9 1100 1105 2-s2.0-0034191863 10.1016/S0002- 9149(00)00703-7 (Pubitemid 30214256)
53. Taylor A. J., Villines T. C., Stanek E. J., Devine P. J., Griffen L., Miller M., Weissman N. J., Turco M., Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England Journal of Medicine 2009 361 22 2113 2122 2-s2.0-72049129430 10.1056/NEJMoa0907569
54. Borberg H., Quo vadis haemapheresis: current developments in haemapheresis. Transfusion and Apheresis Science 2006 34 1 51 73 2-s2.0-32344433168 10.1016/j.transci.2005.11.001 (Pubitemid 43220389)
55. Sakata S., Komaki T., Kojima N., Dynamics of plasma lipoproteins and lipids during double filtration plasmapheresis (DEP). Japanese Journal of Medicine 1987 26 2 176 179 2-s2.0-0023625750 (Pubitemid 17137799)
56. Jaeger B. R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., Parhofer K., Ramlow W., Koch M., Utermann G., Labarrere C. A., Seidel D., Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nature Clinical Practice Cardiovascular Medicine 2009 6 3 229 239 2-s2.0-61549101898 10.1038/ncpcardio1456
57. Hovland A., Marcovina S., Hardersen R., Enebakk T., Mollnes T. E., Lappegård K. T., Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles. Transfusion and Apheresis Science 2012 46 1 73 76 2-s2.0-84857458233 10.1016/j.transci.2011.11. 016
58. Kassner U., Vogt A., Rosada A., Barz F., Giannakidou-Jordan E., Berthold H. K., Steinhagen-Thiessen E., Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atherosclerosis Supplements 2009 10 5 85 88 2-s2.0-72649086379 10.1016/S1567-5688(09)71818-5
59. Chennamsetty I., Claudel T., Kostner K. M., Baghdasaryan A., Kratky D., Levak-Frank S., Frank S., Gonzalez F. J., Trauner M., Kostner G. M., Farnesoid X receptor represses hepatic human APOA gene expression indumathi chennamsetty. Journal of Clinical Investigation 2011 121 9 3724 3734 2-s2.0-80052380574 10.1172/JCI45277
60. Mencarelli A., Fiorucci S., FXR an emerging therapeutic target for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 2010 14 1-2 79 92 2-s2.0-77951942185 10.1111/j.1582-4934.2009.00997.x
61. Busso N., Dudler J., Salvi R., Péclat V., Lenain V., Marcovina S., Darioli R., Nicod P., So A. K., Mooser V., Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints. American Journal of Pathology 2001 159 4 1445 1453 10.1016/S0002-9440(10)62531-X (Pubitemid 32947974)
62. Cesur M., Ozbalkan Z., Temel M. A., Karaarslan Y., Ethnicity may be a reason for lipid changes and high Lp(a) levels in rheumatoid arthritis. Clinical Rheumatology 2007 26 3 355 361 10.1007/s10067-006-0303-5 (Pubitemid 46486966)
63. Zrour S. H., Neffeti F. H., Sakly N., Jguirim M., Korbaa W., Younes M., Bejia I., Touzi M., Fadel N. M., Bergaoui N., Lipid profile in Tunisian patients with rheumatoid arthritis. Clinical Rheumatology 2011 30 10 1325 1331 10.1007/s10067-011-1755-9
64. Park Y. B., Lee S. K., Lee W. K., Suh C. H., Lee C. W., Lee C. H., Song C. H., Lee J., Lipid profiles in untreated patients with rheumatoid arthritis. The Journal of Rheumatology 1999 26 8 1701 1704 (Pubitemid 29367308)
65. Rantapää-Dahlqvist S., Neumann-Andersen G., Backman C., Dahlén G., Stegmayr B., Echocardiographic findings, lipids and lipoprotein(a) in patients with systemic lupus erythematosus. Clinical Rheumatology 1997 16 2 140 148 10.1007/BF02247842 (Pubitemid 27119785)
66. Schultz O., Oberhauser F., Saech J., Rubbert-Roth A., Hahn M., Krone W., Laudes M., Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 2010 5 12 e14328
67. Borba E. F., Santos R. D., Bonfa E., Vinagre C. G., Pileggi F. J., Cossermelli W., Maranhão R. C., Lipoprotein(a) levels in systemic lupus erythematosus. The Journal of Rheumatology 1994 21 2 220 223 (Pubitemid 24078829)
68. George J., Gilburd B., Langevitz P., Levy Y., Nezlin R., Harats D., Shoenfeld Y., β 2 glycoprotein I containing immune-complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels. Lupus 1999 8 2 116 120 (Pubitemid 29103597)